Role of pioglitazone treatment on atrial remodeling and atrial fibrillation (AF)promotion in an experimental model of congestive heart failure.
Korantzopoulos
Panagiotis
P
Goudevenos
John A
JA
Liu
Tong
T
Li
Guangping
G
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D006325:Heart Atria / Q000187:drug effects* / Q000473:pathology; D006333:Heart Failure / Q000139:chemically induced* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007249:Inflammation; D018384:Oxidative Stress; D000077205:Pioglitazone; D011817:Rabbits; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
D047228:Angiotensin II Type 1 Receptor Blockers; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone